Novonesis stock lifts on buyback signal and Q2 beat
Published on 08/21/2026 at 21:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novonesis stock (DK0060336014) drew a fresh bid after Bank of America reiterated its buy call and kept a DKK 500 target, while the shares closed at DKK 450.60 on August 21, 2026. The same note said the company lifted 2026 to 2028 earnings forecasts by 1 percent and highlighted the EUR 1 billion buyback program through 2029. Bank of America commentary reported by MarketScreener
Q2 still shapes the story
The latest consensus page shows 16 analysts, a mean BUY view, and an average target price of DKK 474.50, which sits 4.91 percent above the last close of DKK 452.30. That target spread is useful context for a stock that had already risen 6.12 percent over five days and 10.50 percent year to date on the same market snapshot.
One detail matters for valuation: the bank said Novonesis is growing twice as fast as peers and carries nearly twice the profitability, which helps explain why the premium is being defended. For investors, the mix of a buyback, stronger earnings assumptions, and a target cluster in the DKK 470 to DKK 500 range keeps the debate centered on execution rather than story risk.
Consensus has shifted higher
The same consensus page lists a high target of DKK 540 and a low of DKK 415, showing a narrower range than many industrial peers with more scattered estimates. That kind of spread often matters when a stock has already re-rated, because it leaves less room for another clean upgrade cycle.
Novonesis also trades with a price backdrop that remains firm versus the recent close, and the Danish listing showed DKK 453.40 on the CBOE snapshot for August 20, 2026. The stock's five-day gain there was 9.38 percent, which is enough to keep analyst revisions and buyback mechanics in the foreground.
Novozymes roots still matter
The company remains the world's leading producer of enzymes and microorganisms for industrial customers, with sales spread across agriculture, food, cleaning, and human health. That mix is why the share-price debate now leans on margin quality, not just volume growth.
Shares and valuation
Novonesis stock closed at DKK 450.60 on August 21, 2026, after a 0.38 percent daily decline on the MarketScreener snapshot. With the consensus target at DKK 474.50 and the high at DKK 540, the shares stay positioned between a recent run and a still-positive analyst setup.
More on Novonesis stock
Company: Novonesis A/S
ISIN: DK0060336014
Ticker: NSIS B
Exchange: Nasdaq Copenhagen
Price (as of August 21, 2026): DKK 450.60
Market cap: DKK 211.0 billion
Sector / Industry: Specialty Chemicals / Specialty Chemicals
Index membership: OMX Copenhagen 25
Next earnings date: August 25, 2026
